Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
Work
Year: 2021
Type: article
Source: The Lancet Infectious Diseases
Institutions Duke Raleigh Hospital, Duke Regional Hospital, Duke University Health System, University of California, San Francisco
Cites: 29
Cited by: 182
Related to: 10
FWCI: 11.46
Citation percentile (by year/subfield): 100
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze